Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma, Inc. - Common Stock (NQ: ATHA )

0.5420 +0.0289 (+5.63%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Athira Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More
Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading. 
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Athira Pharma Shares Fall To 52-Week Low - Read Why
Via Benzinga
Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday. 
Via Benzinga
Stocks Quietly Higher as Market Attempts to Extend Rally
Stocks are modestly higher at midday. 
Via Talk Markets
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday. 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract
Exela Technologies (XELA) stock is taking off on Wednesday after gaining a new $136 million customer contract that lasts for three years. 
Via InvestorPlace
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results
Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. 
Via InvestorPlace
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Athira Pharma Stock Is Plunging
Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate... 
Via Benzinga
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
Upgrades 
Via Benzinga
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022
Via Benzinga
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
Earnings Preview: Athira Pharma
Athira Pharma (NASDAQ:ATHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
Via Benzinga
35 Stocks Moving In Friday's Mid-Day Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Athira CEO Resigns After Data Manipulation Firestorm, But Alzheimer's Stock Pops
Athira CEO Leen Kawas resigned after an investigation found she altered images. 
Via Investor's Business Daily
Why Shares of Athira Pharma Are Climbing Today
The clinical trial for its Alzheimer's drug is one step closer to completion. 
Via The Motley Fool
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases
Image by Gerd Altmann from Pixabay How well we think, feel and act rests in the hands of trillions of tiny connectors in our minds. Synapses play an integral role in how we... 
Via Benzinga
NASDAQ:ATHA Long Term Investor Notice: Investigation of Potential Wrongdoing at Athira Pharma, Inc.
San Diego, CA -- (SBWIRE) -- 10/01/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Athira Pharma, Inc. 
Via SBWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.